Trial Profile
A single-arm, non-randomized phase II study to evaluate the gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Nov 2015 New trial record